The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...
The Food and Drug Administration has accepted BridgeBio’s new drug application for acoramidis with a Prescription Drug User Fee Act action date set for Nov. 29. If it receives regulatory approval, ...
It is fair to say that far more individuals aside from the commissioner are instrumental as far as the drug review and ...
The Food and Drug Administration said Wednesday that the U.S. food supply is still "one of the safest in the world," in the wake of a number of foodborne disease outbreaks affecting items ranging ...
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization ...
This page features the latest news about the BridgeBio Pharma stock. Citi maintains buy on BridgeBio stock, raises target to $46 On Friday, Citi reaffirmed its positive stance on BridgeBio Pharma ...